CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics (CTMX), a pioneer in masked, conditionally activated biologics, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Sean McCarthy, CEO and chairman, will engage in a fireside chat on December 4, 2024, at 8:00 a.m. ET. The presentation will be accessible via live webcast on CytomX's website. The company's management team will also be available for individual meetings with registered conference investors.
CytomX Therapeutics (CTMX), pioniere nella biologia attivata condizionatamente e mascherata, ha annunciato la sua partecipazione alla 36陋 Conferenza Annuale sulla Sanit脿 Piper Sandler. Sean McCarthy, CEO e presidente, parteciper脿 a una chiacchierata informale il 4 dicembre 2024 alle 8:00 a.m. ET. La presentazione sar脿 disponibile tramite webcast dal vivo sul sito web di CytomX. Anche il team di gestione dell'azienda sar脿 disponibile per incontri individuali con gli investitori registrati alla conferenza.
CytomX Therapeutics (CTMX), pionero en biol贸gicos activados condicionalmente y enmascarados, ha anunciado su participaci贸n en la 36陋 Conferencia Anual de Salud Piper Sandler. Sean McCarthy, CEO y presidente, participar谩 en un chat informal el 4 de diciembre de 2024 a las 8:00 a.m. ET. La presentaci贸n estar谩 disponible a trav茅s de una transmisi贸n en vivo en el sitio web de CytomX. El equipo de gesti贸n de la compa帽铆a tambi茅n estar谩 disponible para reuniones individuales con los inversores registrados en la conferencia.
靷澊韱办棏鞀� 韰岆澕頁嫳鞀� (CTMX)電� 臁瓣贝攵�搿� 頇滌劚頇旊悳 毵堨姢韨� 靸濍頃欖潣 靹犼惮鞛愲靹� 鞝�36須� 韺岇澊韻� 靸岆摛霟� 項姢旒�鞏� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 靺� 毵レ勾鞁� CEO 瓴� 須岇灔鞚� 2024雲� 12鞗� 4鞚� 鞓れ爠 8鞁�(霃欕秬 響滌鞁�)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃╇媹雼�. 氚滍憸電� CytomX 鞗轨偓鞚错姼毳� 韱淀暣 靸濎瓿勲 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟. 須岇偓鞚� 瓴届榿歆勲弰 霌彪霅� 韴瀽鞛愳檧鞚� 臧滊硠 氙疙寘鞚� 鞙勴暣 雽�旮绊晿瓿� 鞛堨姷雼堧嫟.
CytomX Therapeutics (CTMX), pionnier des bioth茅rapies masqu茅es et activ茅es de mani猫re conditionnelle, a annonc茅 sa participation 脿 la 36猫me Conf茅rence Annuelle de Sant茅 Piper Sandler. Sean McCarthy, PDG et pr茅sident, participera 脿 une discussion informelle le 4 d茅cembre 2024 脿 8h00 HAE. La pr茅sentation sera accessible par webdiffusion en direct sur le site de CytomX. L'茅quipe de direction de l'entreprise sera 茅galement disponible pour des r茅unions individuelles avec les investisseurs enregistr茅s 脿 la conf茅rence.
CytomX Therapeutics (CTMX), ein Pionier im Bereich von maskierten, bedingt aktivierten Biologika, hat seine Teilnahme an der 36. j盲hrlichen Piper Sandler Healthcare Conference 补苍驳别办眉苍诲颈驳迟. Sean McCarthy, CEO und Vorsitzender, wird am 4. Dezember 2024 um 8:00 Uhr ET an einem informellen Gespr盲ch teilnehmen. Die Pr盲sentation wird 眉ber einen Live-Stream auf der Website von CytomX zug盲nglich sein. Das Management-Team des Unternehmens steht auch f眉r pers枚nliche Gespr盲che mit registrierten Konferenzteilnehmern zur Verf眉gung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.
A live webcast of the presentation will be available on the Events and Presentations page of CytomX鈥檚 website at . In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About聽CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY庐 therapeutic platform, CytomX鈥檚 vision is to create safer, more effective therapies for the treatment of cancer. CytomX鈥檚 robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (鈥淎DCs鈥�), T-cell engagers, and immune modulators such as cytokines. CytomX鈥檚 clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY庐 cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas,聽Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit聽聽and follow us on聽听补苍诲听聽(formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
Media Contact:
Redhouse Communications
Teri Dahlman
FAQ
When is CytomX Therapeutics (CTMX) presenting at the Piper Sandler Healthcare Conference 2024?
How can investors watch CytomX Therapeutics' (CTMX) presentation at the Piper Sandler Conference?
Will CytomX Therapeutics (CTMX) management be available for investor meetings at the Piper Sandler Conference?
What type of presentation will CytomX Therapeutics (CTMX) give at the Piper Sandler Healthcare Conference?
